We are live on ! Find out more
YMAB

Y-mAbs Therapeutics
YMAB

Delisted

YMAB was delisted on the 15th of September, 2025.

Back to rankings

100 hedge funds and large institutions have $303M invested in Y-mAbs Therapeutics in 2022 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 29 increasing their positions, 32 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

129% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 7

10% more funds holding

Funds holding: 91 → 100 (+9)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

9% less repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 32

2.75% less ownership

Funds ownership: 56.64% → 53.89% (-2.8%)

8% less capital invested

Capital invested by funds: $330M → $303M (-$26.8M)

Holders
100
Holders Change
+9
Holders Change %
+9.89%
% of All Funds
1.72%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
16
Increased
29
Reduced
32
Closed
7
Calls
$1.78M
Puts
–
Net Calls
+$1.78M
Net Calls Change
-$802K

Top Buyers

Rank Fund Capital Flow
1
DCM
Driehaus Capital Management
Illinois
+$4.92M
2
State Street
State Street
Massachusetts
+$2.91M
3
Citadel Advisors
Citadel Advisors
Florida
+$1.5M
4
Wellington Management Group
Wellington Management Group
Massachusetts
+$1.29M
5
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$1.23M

Top Sellers

Rank Fund Capital Flow
1
AllianceBernstein
AllianceBernstein
Tennessee
-$11M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$9.81M
3
PCH
Polar Capital Holdings
United Kingdom
-$6.97M
4
Morgan Stanley
Morgan Stanley
New York
-$1.97M
5
Invesco
Invesco
Georgia
-$1.63M
Name Holding Trade Value Shares
Change 		Change in
Stake
CSS
76
Cubist Systematic Strategies
Connecticut
$144K -$8.98K -542 -5%
ACM
77
Aquatic Capital Management
Illinois
$108K +$124K +7,500 New
Zurich Cantonal Bank
78
Zurich Cantonal Bank
Switzerland
$94K – – –
AB
79
Amalgamated Bank
New York
$84K +$1.52K +92 +2%
Royal Bank of Canada
80
Royal Bank of Canada
Ontario, Canada
$84K +$4.92K +297 +5%
AIP
81
Ameritas Investment Partners
Nebraska
$38K – – –
PCH
82
Polar Capital Holdings
United Kingdom
$36.5K -$6.97M -421,125 -14%
MLICM
83
Metropolitan Life Insurance Company (MetLife)
New York
$33.2K – – –
Simplex Trading
84
Simplex Trading
Illinois
$27K +$22.3K +1,348 +253%
Allspring Global Investments
85
Allspring Global Investments
North Carolina
$25K -$47.9K -2,891 -62%
Osaic Holdings
86
Osaic Holdings
Arizona
$24K +$27.9K +1,683 New
TRCT
87
Tower Research Capital (TRC)
New York
$23K -$43.1K -2,600 -62%
Canada Life
88
Canada Life
Manitoba, Canada
$21K – – –
Wells Fargo
89
Wells Fargo
California
$18K -$4.01K -242 -16%
Russell Investments Group
90
Russell Investments Group
United Kingdom
$11K +$13.5K +816 New
HWM
91
HighMark Wealth Management
Minnesota
$10K – – –
LC
92
Lindbrook Capital
California
$9K +$99 +6 +1%
Macquarie Group
93
Macquarie Group
Australia
$7K -$4.34K -262 -56%
Nisa Investment Advisors
94
Nisa Investment Advisors
Missouri
$7K +$646 +39 +2%
CUAMC
95
China Universal Asset Management Company
China
$6K +$6.79K +410 New
Daiwa Securities Group
96
Daiwa Securities Group
Japan
$2K – – –
AF
97
Allworth Financial
California
$1K – – –
EBA
98
Eagle Bay Advisors
New York
$1K – – –
QC
99
Quent Capital
New York
$1K – – –
Allianz Asset Management
100
Allianz Asset Management
Germany
– -$485K -32,085 Closed
1 2 3
4
5

YMAB Hedge Fund Activity: Q3 2022 in Review

100 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Y-mAbs Therapeutics (YMAB) for Q3 2022, worth a combined $303M — down 8.1% from $330M a quarter earlier.

Buyers outnumbered sellers: 16 funds opened new YMAB positions and 7 closed out — a net gain of 9 holders — while 29 added to existing stakes and 32 trimmed.

The largest buyer was Driehaus Capital Management, opening a new position worth an estimated $4.92M. The largest seller was AllianceBernstein, cutting an estimated $11M.

  • 100 institutional investors held Y-mAbs Therapeutics (YMAB) as of Q3 2022, up from 91 in Q2 2022.
  • Funds reported $303M of Y-mAbs Therapeutics stock for Q3 2022, down 8.1% quarter-over-quarter.
  • 16 funds opened new Y-mAbs Therapeutics positions in Q3 2022 and 7 closed out, a net change of +9 holders.
  • The largest Y-mAbs Therapeutics buyer in Q3 2022 was Driehaus Capital Management, an estimated $4.92M added.
  • The largest Y-mAbs Therapeutics seller in Q3 2022 was AllianceBernstein, an estimated $11M sold.

Based on aggregated 13F filings for Q3 2022.